

General information about company	
Scrip code*	531146
NSE Symbol*	MEDICAMEQ
MSEI Symbol*	NOTLISTED
ISIN*	INE646B01010
Name of company	MEDICAMEN BIOTECH LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	12-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	07-08-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	12-08-2025 12:00
End date and time of board meeting	12-08-2025 15:30

Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-06-2025	30-06-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	3844.9	3844.9	
	Other income	47.03	47.03	
	Total income	3891.93	3891.93	
2	Expenses			
(a)	Cost of materials consumed	2387.78	2387.78	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-188.49	-188.49	
(d)	Employee benefit expense	530.53	530.53	
(e)	Finance costs	56.22	56.22	
(f)	Depreciation, depletion and amortisation expense	177.3	177.3	
(g)	Other Expenses			
1	Other Expenses	711.65	711.65	

	Total other expenses	711.65	711.65
	Total expenses	3674.99	3674.99
3	Total profit before exceptional items and tax	216.94	216.94
4	Exceptional items	0	0
5	Total profit before tax	216.94	216.94
6	Tax expense		
7	Current tax	56.95	56.95
8	Deferred tax	-3.68	-3.68
9	Total tax expenses	53.27	53.27
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	163.67	163.67
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	163.67	163.67
17	Other comprehensive income net of taxes	0	0
18	Total Comprehensive Income for the period	163.67	163.67
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		

	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	1356.28	1356.28	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	1.21	1.21	
	Diluted earnings (loss) per share from continuing operations	1.21	1.21	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	1.21	1.21	
	Diluted earnings (loss) per share from continuing and discontinued operations	1.21	1.21	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Other Comprehensive Income				
		Date of start of reporting period	01-04-2025	01-04-2025
		Date of end of reporting period	30-06-2025	30-06-2025
		Whether results are audited or unaudited	Unaudited	Unaudited
		Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss			
	Total Amount of items that will not be reclassified to profit and loss			
2	Income tax relating to items that will not be reclassified to profit or loss			
3	Amount of items that will be reclassified to profit and loss			
	Total Amount of items that will be reclassified to profit and loss			
4	Income tax relating to items that will be reclassified to profit or loss			
5	Total Other comprehensive income			

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	24-04-2025
Amount Raised	5356.81
Report filed for Quarter ended	30-06-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	There is no deviation/variation in the utilization of funds
Comments of the auditors, if any	NA

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
1	<p>The Company intends to utilize the proceeds raised through the issue of Equity Shares and Fully Convertible Warrants (“Issue Proceeds”) towards the following objects: a) Drug Development of 50 SKUs for Regulated markets: The company intends to develop 50 SKUs in oncology, diabetes, and cardiovascular diseases (CVD) for regulated markets such as the US, EU, Canada, and Australia. The development process requires significant investment in: • Procurement of R&D quantities of new molecules. • Formulation development, analytical method validation, and stability studies across different climatic zones. • Execution of engineering and validation batches, including process validation and stability studies. • Import of Reference Listed Drugs (RLDs) and conducting in vitro Comparative Dissolution Profile (CDP) and Bioequivalence (BE) studies, which involve substantial costs. b) Registration of dossiers, etc.: • Preparation and submission of Electronic common technical document (eCTD) which contains all information and documents of product development for product registration in regulated markets, requiring highly skilled personnel and outsourcing of non-clinical data. • Payment of high regulatory fees, which are mandatory at the time of dossier submission. c) Meet the Enhanced working capital requirements: • Augmenting resources for Quality Control (QC) and Quality Assurance (QA) at manufacturing facilities. • Recruitment of experienced international marketing professionals to drive expansion in regulated markets. • Strengthening distribution and sales networks to</p>	NA	5356.81	0	1453.72	0	

<p>support market penetration. d) Capital expenditure in some area of upgradation of the existing facilities: In the existing facilities of the Company, Capex is required to be undertaken for additional instruments, packaging machines, and compliance tools to meet country-specific regulatory requirements for new products. e) Expansion of operations in Domestic Market: • Strengthening the company's footprint in oncology, diabetes, and CVD segments by establishing new regional headquarters across India. • Expansion of the salesforce, including the recruitment of 200+ field representatives and managers. • Increased participation in domestic medical conferences to enhance brand recognition and engagement with healthcare professionals. f) General Corporate Purposes</p>						
--	--	--	--	--	--	--

Signatory Details	
Name of signatory	Parul Choudhary
Designation of person	Company Secretary and Compliance Officer
Place	New Delhi
Date	12-08-2025

Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No.	Particulars	Amount	Remarks
1.	Loans / revolving facilities like cash credit from banks / financial institutions		
A	Total amount outstanding as on date	2549.37	
B	Of the total amount outstanding, amount of default as on date	0	
2.	Unlisted debt securities i.e. NCDs and NCRPS		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0	

